# US 2021/0275573 A1 · Anti-virus agent and method for treatment of viral infection > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2021/0275573 A1 - Document ID: US20210275573A1 - Status: Published application - Kind: A1 - Application number: 17/326,995 - Filed: 2021-05-21 - Published: 2021-09-09 - Earliest claimed: 2016-02-19 - Assignees: Recce Limited - Applicants: Recce Limited - Inventors: Graham John Hamilton MELROSE; Michele Keryn DILIZIA - Web page: https://patentgrep.com/patent/US20210275573A1 ## CPC - A61K 31/78: of acrylic acid or derivatives thereof - A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)} - A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration} - A61K 9/0073: {Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M)} - A61K 9/20: Pills, tablets, {discs, rods (A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095)} - A61K 9/48: Preparations in capsules, e.g. of gelatin, of chocolate {(A61K9/0004 takes precedence; bite capsules A61K9/0056)} - A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers - A61P 31/16: for influenza or rhinoviruses - A61P 31/18: for HIV - A61P 31/22: for herpes viruses - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract A method of treatment of viral infection in a subject comprising administering to the subject a copolymer comprising an acrolein derived segment or a polyacrolein oligomer segment and a polyalkylene glycol oligomer segment, the copolymer having a molecular weight of no more than 1500 Daltons. ## Claims ### Claim at position 1 -30. (canceled) ### Claim 31 A method of treatment of a parenteral viral infection in a subject comprising administering to the subject a copolymer comprising an acrolein-derived segment and a polyalkylene glycol oligomer segment, the copolymer having a molecular weight of no more than 1000 Daltons. ### Claim 32 (depends on 31) The method according to claim 31, wherein the acrolein-derived segment is a polyacrolein oligomer comprising two or more acrolein residues. ### Claim 33 (depends on 31) The method according to claim 31, wherein the copolymer has a molecular weight of from 300 to 1000 Daltons. ### Claim 34 (depends on 31) The method according to claim 31, wherein the polyalkylene glycol oligomer segment has a molecular weight in the range of from 200 to 600 Daltons. ### Claim 35 (depends on 31) The method according to claim 31, wherein the polyalkylene glycol oligomer segment has a molecular weight in the range of from 200 to 400 Daltons. ### Claim 36 (depends on 31) The method according to claim 31, wherein a polyalkylene glycol of the polyalkylene glycol oligomer segment is polyethylene glycol. ### Claim 37 (depends on 31) The method according to claim 31, wherein the copolymer has a molecular weight of from 400 to 800 Daltons. ### Claim 38 (depends on 31) The method according to claim 31, wherein the copolymer is administered systemically. ### Claim 39 (depends on 31) The method according to claim 31, wherein the copolymer is administered by a route selected from the group consisting of oral administration, inhalation, transdermal delivery and injection. ### Claim 40 (depends on 31) The method according to claim 31, wherein the copolymer is administered by oral administration. ### Claim 41 (depends on 31) The method according to claim 31, wherein the copolymer is administered by intravenous injection or infusion. ### Claim 42 (depends on 31) The method according to claim 31, wherein the copolymer is administered as an aqueous solution comprising a copolymer concentration in the range of from 0.01% by weight to 20% by weight of the aqueous solution. ### Claim 43 (depends on 31) The method according to claim 31, wherein the copolymer is administered orally in the form of a tablet, caplet, syrup or liquid. ### Claim 44 (depends on 31) The method according to claim 31, wherein the copolymer is administered systemically at a dose in the range of from 1 mg to 1000 mg per kilogram of bodyweight per day. ### Claim 45 (depends on 31) The method according to claim 31, wherein the parenteral viral infection is selected from the group consisting of a influenza viral infection, an HIV infection, a hepatitis viral infection, a Ross River viral infection, and a herpes viral infection. ### Claim 46 (depends on 31) The method according to claim 31, wherein the parenteral viral infection is an influenza viral infection. ### Claim 47 A process of preparing a copolymer comprising an acrolein-derived segment and a polyalkylene glycol oligomer comprising: adding a first aqueous solution comprising an acrolein having an acrolein concentration of no more than 50% w/w by weight of the first aqueous solution to a second aqueous solution comprising polyethylene glycol and at least 10% w/w water by weight of the second aqueous solution; thereby forming a third aqueous solution; and polymerizing the acrolein under conditions of alkaline catalysis at a pH no more than 12 in the third aqueous solution, and thereby forming a copolymer, wherein: the molecular weight of the polyalkylene glycol is from 200 to 600 Daltons and the copolymer has a molecular weight of no more than 1000 Daltons; the second aqueous solution has a pH of no more than 12.0; the third aqueous solution comprises at least 20% w/w water by weight of the third aqueous solution; and the copolymer has a weight ratio of polyalkylene glycol:acrolein of at least 4:1. ### Claim 48 (depends on 47) The process according to claim 47, wherein the second aqueous solution has a pH of from 9 to 11. ### Claim 49 (depends on 47) The process according to claim 47, wherein: the second aqueous solution is a mildly basic aqueous solution having a pH of no more than 12.0; the polyalkylene glycol has a molecular weight in the range of from 200 to 600 Daltons; the mildly basic solution is stirred vigorously to entrain air; the first aqueous solution is added over a period of at least 2 minutes the polymerization temperature is maintained in the range of from 10° C. to 40° C.; and acid is added to provide a pH less than 9 once the acrolein has been consumed. ### Claim 50 A copolymer effective in treatment of parenteral viral infection in a subject by systemic administration, the copolymer comprising an acrolein-derived segment and a polyalkylene glycol oligomer segment wherein: the copolymer has a molecular weight of no more than 1000 Daltons; and the polyalkylene glycol oligomer segment has a molecular weight in the range of 200 to 600 Daltons.